tldrdailynews.com logo

FDA Advisors Endorse JN.1-Based COVID Vaccine for Fall

1 min read
Source: CNN
FDA Advisors Endorse JN.1-Based COVID Vaccine for Fall
Photo: CNN
TL;DR

The FDA's advisory committee has unanimously recommended updating the Covid-19 vaccine to target the JN.1 lineage for the 2024-2025 season. This new monovalent vaccine aims to improve protection against the most common variants currently in circulation. The decision now awaits full FDA approval, with manufacturers like Pfizer, Moderna, and Novavax prepared to supply the updated shots by fall. Despite low current Covid-19 cases and hospitalizations, experts emphasize the need for updated vaccinations to maintain protection, especially as immunity from previous shots wanes over time.

Topics:businesshealth#covid-19#fda#health#jn1-variant#public-health#vaccine
Share this article
  1. FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall  CNN
  2. FDA panel supports switch to JN.1 for fall COVID vaccines  University of Minnesota Twin Cities
  3. COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say  Reuters
  4. FDA Advisors Give a Hearty Thumbs Up to a COVID Vaccine Based on the JN.1 Strain  Medpage Today
  5. New Covid Vaccine Endorsed for Fall  The New York Times

Want the full story? Read the original reporting

Read on CNN